Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand …
Over the last 12 months, insiders at Tonix Pharmaceuticals Holding Corp. have bought $0 and sold $0 worth of Tonix Pharmaceuticals Holding Corp. stock.
On average, over the past 5 years, insiders at Tonix Pharmaceuticals Holding Corp. have bought $73,833 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $34,200 was made by LEDERMAN SETH (Chief Executive Officer) on 2022‑06‑29.
2022-06-29 | Chief Executive Officer | 20,000 0.0147% | $1.71 | $34,200 | -66.14% | |||
2022-03-25 | Chief Executive Officer | 100,000 0.0033% | $0.24 | $24,500 | -85.39% | |||
2021-09-28 | Chief Executive Officer | 12,000 <0.0001% | $0.61 | $7,320 | -66.66% | |||
2021-05-25 | director | 5,000 <0.0001% | $1.12 | $5,600 | -56.78% | |||
2021-03-24 | Chief Executive Officer | 16,733 <0.0001% | $1.32 | $22,088 | -51.21% | |||
2020-12-30 | Chief Executive Officer | 35,000 0.0001% | $0.68 | $23,800 | +41.83% | |||
2020-08-31 | director | 5,500 <0.0001% | $0.89 | $4,895 | +9.38% | |||
2020-08-20 | director | 5,391 <0.0001% | $0.93 | $4,997 | +4.67% | |||
2020-08-17 | Chief Medical Officer | 20,000 <0.0001% | $1.03 | $20,600 | -5.45% | |||
2020-08-14 | director | 4,500 <0.0001% | $1.06 | $4,770 | -4.06% | |||
2020-08-13 | Chief Executive Officer | 60,000 0.0002% | $0.91 | $54,600 | -14.11% | |||
2020-08-13 | director | 10,000 <0.0001% | $0.91 | $9,100 | -14.11% | |||
2020-08-13 | director | 5,350 <0.0001% | $0.94 | $5,029 | -14.11% | |||
2019-12-03 | Chief Executive Officer | 20,000 1.2754% | $1.16 | $23,180 | -33.19% | |||
2019-03-29 | Chief Executive Officer | 5,000 0.0005% | $2.49 | $12,440 | -82.15% | |||
2019-03-26 | Chief Executive Officer | 25,000 0.0025% | $2.38 | $59,375 | -82.14% | |||
2018-06-29 | Chief Executive Officer | 500 <0.0001% | $4.64 | $2,320 | -94.76% | |||
2018-06-28 | Chief Executive Officer | 500 <0.0001% | $4.58 | $2,290 | -94.91% | |||
2018-06-27 | Chief Executive Officer | 500 <0.0001% | $4.55 | $2,275 | -94.91% | |||
2018-06-25 | director | 16,500 0.001% | $4.48 | $73,920 | -94.75% |
Moss David J | PRES, CEO, TRES, CFO, SECR | 3250000 1.739% | $0.39 | 1 | 0 | |
DAUGHERTY BRUCE | See remarks | 100000 0.0535% | $0.39 | 6 | 0 | |
Saks Samuel R | director | 51050 0.0273% | $0.39 | 3 | 0 | |
MARIO ERNEST | director | 50000 0.0268% | $0.39 | 17 | 7 | |
LEDERMAN SETH | Chief Executive Officer | 24235 0.013% | $0.39 | 40 | 0 | <0.0001% |